Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznanie transformacji raka na typ małokomórkowy
- •Wcześniejsze rozpoznanie raka płuca z mutacją EGFR i leczenie osimertinibem
- •Możliwość zmierzenia choroby w badaniach obrazowych
- •Zadowalające wyniki badań krwi i funkcji wątroby oraz nerek
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG ≤ 2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, United States
Trial contact
Lori Tyson, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.